Abstract
Computational semantics, a branch of computational linguistics, involves automated meaning analysis that relies on how words occur together in natural language. This offers a promising tool to study schizophrenia. At present, we do not know if these word level choices in speech are sensitive to illness stage (i.e. acute untreated vs. stable established state), track cognitive deficits in major domains (e.g. cognitive control, processing speed) and relate to established dimensions of formal thought disorder. Here we study samples of descriptive discourse in patients with untreated first episode of schizophrenia (x□ 2.8 days of lifetime daily dose exposure) and healthy subjects (246 samples of 1-minute speech; n=82, FES=46, HC=36) using a co-occurrence based vector embedding of words. We obtained six-month follow-up data in a subsample (99 speech samples, n=33, FES=20, HC=13). At baseline, the evidence for higher semantic similarity during descriptive discourse in FES was substantial, compared to null difference (Bayes Factor =6 for full description; 32 for 10-words window). Moreover, the was a linear increase in semantic similarity with time in FES compared to HC (Bayes Factor= 6). Higher semantic similarity related to lower Stroop performance (accuracy and interference, response time), and was present irrespective of the severity of clinically ascertained thought disorder. Automated analysis of non-intrusive 1-minute speech samples provides a window on cognitive control deficits, role functioning and tracks latent progression in schizophrenia.
Competing Interest Statement
LP reports personal fees from Otsuka Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Janssen Canada, Sunovion and Otsuka Canada outside the submitted work. LP is the convenor of the DISCOURSE in psychosis consortium (www.discourseinpsychosis.org). All other authors report no relevant conflicts.
Funding Statement
This study was funded by The Canadian Institutes of Health Research (CIHR) Foundation Grant (375104/2017). This work was also supported by the National Agency for Research and Development (ANID), Scholarship Program, Becas Chile 2019, Postdoctoral Fellow 74200048 (MA); Parkwood Institute Studentship and the Jonathan and Joshua Memorial Scholarship to MM; We also acknowledge support from the Bucke Family Fund, The Chrysalis Foundation and The Arcangelo Rea Family Foundation (London, Ontario).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent before assessment and ethics approval was granted by the Human Research Ethics Board at Western University, London, Ontario.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request
